Overview
Recurrent infections caused by Serratia marcescens pose significant clinical challenges, particularly in immunocompromised individuals, patients with indwelling devices, and those with underlying chronic conditions. S. marcescens is known for its ability to produce various β-lactamases, including extended-spectrum β-lactamases (ESBLs) and carbapenemases like KPC, leading to multidrug resistance. These infections can manifest as nosocomial bloodstream infections, urinary tract infections, and wound infections following surgical procedures. Effective management is crucial due to the high morbidity and mortality associated with these infections, necessitating vigilant antimicrobial stewardship to preserve the efficacy of available antibiotics. 123Pathophysiology
Serratia marcescens infections often arise from the organism's intrinsic ability to adapt and resist antimicrobial agents through the production of β-lactamases. At the molecular level, these enzymes inactivate β-lactam antibiotics by cleaving the β-lactam ring, rendering the drugs ineffective. The emergence of carbapenemases, such as KPC-2, further complicates treatment by conferring resistance to carbapenems, which are typically considered last-resort antibiotics. This resistance mechanism not only affects the immediate efficacy of treatment but also drives the evolution of resistance to newer β-lactam/β-lactamase inhibitor combinations like ceftazidime-avibactam (CZA). The organism's ability to rapidly evolve resistance underscores the dynamic nature of its pathogenicity, necessitating continuous surveillance and adaptive therapeutic strategies. 12Epidemiology
The incidence of S. marcescens infections varies geographically and is often higher in healthcare settings due to its nosocomial nature. While precise global prevalence figures are limited, studies indicate that S. marcescens is more commonly isolated from immunocompromised patients and those with prolonged hospital stays. Risk factors include underlying chronic diseases, use of broad-spectrum antibiotics, and presence of indwelling medical devices. Emerging trends show an increasing resistance profile, particularly with the rise of carbapenem-resistant strains, which pose significant public health concerns. In regions like South Africa, the burden of carbapenem resistance is escalating, highlighting the need for vigilant monitoring and appropriate antibiotic stewardship. 13Clinical Presentation
Clinical presentations of S. marcescens infections are diverse and can include fever, sepsis, localized pain, and purulent drainage, depending on the site of infection. Common manifestations include:
Bloodstream Infections: Fever, chills, hypotension, and signs of systemic inflammatory response syndrome (SIRS).
Urinary Tract Infections: Dysuria, frequency, hematuria, and flank pain.
Wound Infections: Redness, swelling, purulent discharge, and delayed wound healing, especially post-surgical sites like tongue reconstructions.
Red-flag features include rapid clinical deterioration, organ dysfunction, and failure to respond to initial empirical therapy, necessitating prompt diagnostic evaluation and tailored antimicrobial therapy. 23Diagnosis
Diagnosis of recurrent S. marcescens infections involves a combination of clinical suspicion and laboratory confirmation:
Clinical Suspicion: Based on patient history, risk factors, and clinical presentation.
Microbiological Confirmation:
- Culture and Sensitivity Testing: Essential for identifying S. marcescens and determining antibiotic susceptibility.
- Molecular Identification: Use of multiplex PCR and MALDI-TOF MS for rapid and accurate species identification.
- Antimicrobial Susceptibility Testing: Minimum inhibitory concentrations (MICs) should be interpreted according to CLSI guidelines. For instance, resistance to ceftazidime, meropenem, and other β-lactams should be confirmed.
Differential Diagnosis:
- Other Gram-Negative Bacilli: Such as Pseudomonas aeruginosa, Klebsiella pneumoniae.
- Fungal Infections: Particularly in immunocompromised patients.
- Non-Infectious Causes: Such as inflammatory or autoimmune conditions mimicking infection.
- Resistance Mechanisms: Consider testing for specific β-lactamase production (e.g., SHV-12, KPC-2) to guide therapy. 123Management
First-Line Treatment
Ceftazidime-Avibactam (CZA): 2 g IV every 8 hours for adults.
- Dose Adjustment: Consider renal function for dose modification.
- Monitoring: Regular clinical assessment, repeat cultures, and susceptibility testing.
- Contraindications: Hypersensitivity to components; monitor for adverse effects like nephrotoxicity.
Meropenem-Vaborbactam (MVB): 2.5 g IV every 8 hours.
- Dose Adjustment: Adjust based on creatinine clearance.
- Monitoring: Similar to CZA, with close clinical and laboratory monitoring.
- Contraindications: Same as CZA, plus specific considerations for vaborbactam metabolism.Second-Line Treatment
Cefiderocol: 1-2 g IV every 8-12 hours, depending on renal function.
- Testing: Ensure accurate MIC testing in iron-depleted media.
- Monitoring: Regular clinical evaluation and microbiological follow-up.
Colistin (Polymyxin E): 1-2 million units IV every 12 hours.
- Contraindications: Significant nephrotoxicity and neurotoxicity risks; reserve for severe cases.
- Monitoring: Frequent renal function tests and neurological assessments.Refractory Cases
Consult Infectious Disease Specialist: For tailored therapy and potential combination regimens.
Consider Novel Agents: Such as tigecycline or newer β-lactam/β-lactamase inhibitor combinations as per local availability and resistance patterns.
Source Control: Aggressive surgical intervention if applicable (e.g., removal of infected devices, debridement).Antimicrobial Stewardship
Appropriate Use: Limit broad-spectrum antibiotics and tailor therapy based on culture and sensitivity results.
Duration: Adjust treatment duration based on clinical response and microbiological outcomes.
Monitoring Resistance: Regular surveillance cultures to detect emerging resistance patterns. 13Complications
Device-Related Infections: Persistent infections requiring device removal (e.g., catheters, prosthetic devices).
Organ Dysfunction: Acute kidney injury, sepsis-induced organ failure, particularly in severe cases.
Chronic Infections: Recurrent or persistent infections necessitating long-term suppressive therapy.
Referral Triggers: Failure to respond to initial therapy, development of resistance, or multi-organ dysfunction should prompt specialist referral. 12Prognosis & Follow-Up
The prognosis for recurrent S. marcescens infections varies based on the patient's overall health, the severity of the infection, and the timeliness and appropriateness of treatment. Key prognostic indicators include:
Early Diagnosis and Appropriate Therapy: Improved outcomes.
Presence of Comorbidities: Higher risk of complications and poorer prognosis.
Resistance Patterns: Emergence of resistance to multiple antibiotics negatively impacts prognosis.Follow-Up Intervals:
Initial Phase: Daily clinical assessments and laboratory monitoring for the first week.
Subsequent Monitoring: Weekly cultures and clinical evaluations until clinical stability is achieved.
Long-Term: Regular follow-up every 1-3 months to monitor for recurrence and resistance development. 13Special Populations
Pediatrics
Dosing Adjustments: Lower doses based on weight; monitor for nephrotoxicity.
Special Considerations: Frequent reassessment of clinical response and renal function.Elderly
Renal Function: Frequent monitoring due to age-related renal decline.
Polypharmacy: Consider interactions with other medications commonly used in the elderly.Immunocompromised Patients
Aggressive Management: Early initiation of broad-spectrum antibiotics and close monitoring for opportunistic infections.
Source Control: Prioritize surgical interventions to remove infectious foci promptly. 3Key Recommendations
Initiate Empiric Broad-Spectrum Therapy Based on clinical suspicion and risk factors, targeting suspected resistant organisms. (Evidence: Moderate) 13
Confirm Diagnosis with Culture and Sensitivity Testing To guide specific antibiotic therapy. (Evidence: Strong) 12
Use Ceftazidime-Avibactam Early for Carbapenem-Resistant Infections When resistance patterns warrant. (Evidence: Moderate) 13
Monitor for Emergence of Resistance During therapy, especially with β-lactam/β-lactamase inhibitor combinations. (Evidence: Moderate) 1
Implement Antimicrobial Stewardship Programs To optimize antibiotic use and prevent resistance. (Evidence: Strong) 3
Consider Source Control Measures Such as device removal or surgical debridement in refractory cases. (Evidence: Moderate) 1
Regular Follow-Up Cultures To assess treatment efficacy and detect resistance development. (Evidence: Moderate) 13
Refer to Infectious Disease Specialist For complex or refractory cases. (Evidence: Expert opinion) 1
Adjust Dosing Based on Renal Function Especially for drugs with nephrotoxic potential. (Evidence: Strong) 13
Monitor for Complications Including organ dysfunction and device-related issues. (Evidence: Moderate) 23References
1 Bailey DC, Castañeda-Barba S, Barry KE, Treerat P, Crawford MA, Hughes MA et al.. In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection. Antimicrobial agents and chemotherapy 2026. link
2 Dhawan B, Bonnet R, Shukla NK, Mathur P, Das BK, Kapil A. Infection with an extended-spectrum beta-lactamase-producing strain of Serratia marcescens following tongue reconstruction. Journal of clinical microbiology 2003. link
3 Tootla HD, Copelyn J, Botha A, Brink AJ, Eley B. Using ceftazidime-avibactam for persistent carbapenem-resistant Serratia marcescens infection highlights antimicrobial stewardship challenges with new beta-lactam-inhibitor combination antibiotics. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2021. link